Navitoclax and sickle cell disease: senolytic hypothesis from St. Jude
A pending St. Jude patent proposes treating sickle cell disease by targeting senescent cells and reports navitoclax restored HSC function in SCD mice; the available excerpt provides no dose, sample size, statistical analysis, or human evidence.
St. Jude Children's Research Hospital filed international patent application WO2025064402A1 (published March 27, 2025; inventors Shannon McKinney-Freeman and Aditya Barve). The application describes a method for treating sickle cell disease by targeting senescent cells. According to the application, navitoclax increased hematopoietic stem and progenitor cells (HSPCs) and restored hematopoietic stem cell (HSC) function in mice with sickle cell disease.
Navitoclax (ABT-263), a BCL-2 family inhibitor, is one of the first senolytics discovered, alongside dasatinib, quercetin, and fisetin. Senolytics selectively clear senescent cells, which accumulate with ageing and are often resistant to apoptosis (controlled cell death). The apparent reasoning of the application is that senescent cells impair hematopoiesis in sickle cell disease, and that clearing them with navitoclax restores stem cell function. The available excerpt does not contain data confirming this causal link.
The excerpt reports no navitoclax dose, sample size, or statistical analysis. Whether disease manifestations improved in the mice, or the effect was limited to laboratory measures of stem cell number and function, is not stated. No human efficacy or safety evidence for navitoclax in sickle cell disease appears in this source.
WO2025064402A1, St. Jude · Navitoclax on Eternal Search
Sources
[1] Method for treating sickle cell disease by targeting senescent cells
The edge places an established senolytic benchmark compound inside a genetic blood disease context, showing that the senolytic hypothesis is being tested beyond aging. The patent is recent, pending, and carries a concrete mouse result, making the connection worth tracking rather than dismissing as speculative noise.